In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and a leading
cause of cancer-related deaths worldwide. Ninety percent of HCC cases arise from cirrhosis …

Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations
in genotype prevalence. This poses a challenge to the improved development of vaccines …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …

Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder sexuelle Gewalt
erfahren Page 1 Gesundheitliche Versorgung von Frauen, die Gewalt in der Paarbeziehung oder …

Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited,
with the currently approved all‐oral regimens requiring 24‐week treatment and the addition …

Background High rates of sustained virologic response were observed among patients with
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …

Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …

Background In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in
previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 …